Rachael Lester
Corporate Officer/Principal at HARPOON THERAPEUTICS, INC.
Network origin in Rachael Lester first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Biotechnology | 26 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Rachael Lester via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Operating Officer | |
| EXELIXIS, INC. | Pharmaceuticals: Major | General Counsel Chief Tech/Sci/R&D Officer | |
| ARRAY TECHNOLOGIES, INC. | Pharmaceuticals: Major | Chief Operating Officer | |
| SEAGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director/Board Member Chairman | |
Serenex, Inc.
 Serenex, Inc. Pharmaceuticals: MajorHealth Technology Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Founder | |
Waratah Pharmaceuticals, Inc.
 Waratah Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million. | Medical Specialties | Founder | |
| HOSPIRA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Idun Pharmaceuticals, Inc.
 Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member | |
Gene Solutions LLC
 Gene Solutions LLC BiotechnologyHealth Technology Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA. | Biotechnology | Director/Board Member | |
ImmuRx, Inc.
 ImmuRx, Inc. BiotechnologyHealth Technology ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| ASTERIAS BIOTHERAPEUTICS INC | Biotechnology | Director of Finance/CFO Comptroller/Controller/Auditor | |
| COGENT BIOSCIENCES, INC. | Biotechnology | Chief Executive Officer | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| Swarthmore College | College/University | Undergraduate Degree | |
| University of California, Davis | College/University | Undergraduate Degree | |
| The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel | |
| FATE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Science Magazine
 Science Magazine Internet Software/ServicesTechnology Services Science Magazine is a peer-reviewed academic journal published by the American Association for the Advancement of Science. It is one of the top academic journals in the world and has been in circulation since 1880. The magazine delivers impactful research, daily news, expert commentary, and career resources to its subscriber base of around 130,000. Science is a leading multidisciplinary, international journal that covers breakthroughs and policy analysis and news. | Internet Software/Services | Director of Finance/CFO | |
| RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO | |
| Harvard T.H. Chan School of Public Health | College/University | Graduate Degree Graduate Degree | |
| The University of Chicago Booth School of Business | College/University | Masters Business Admin | |
Beal Advisors LLC
 Beal Advisors LLC Investment ManagersFinance Beal Advisors LLC provides investment advice services. The private company is based in Walnut Creek, CA. The company was founded by Georgia L. Erbez. | Investment Managers | Founder | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Kellogg School of Management | College/University | Masters Business Admin | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director of Finance/CFO Chief Executive Officer | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director of Finance/CFO | |
| ITERUM THERAPEUTICS PLC | Pharmaceuticals: Major | Chairman Director/Board Member | |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder | |
Iterum Therapeutics International Ltd.
 Iterum Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Iterum Therapeutics International Ltd. engages in the development of clinical-stage pharmaceutical products. The company was founded in 2015 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Iterum Therapeutics US Holding Ltd.
 Iterum Therapeutics US Holding Ltd. Financial ConglomeratesFinance Iterum Therapeutics US Holding Ltd. operates as a clinical-stage pharmaceutical company. The company was founded in 2018 and is headquartered in Chicago, IL. | Financial Conglomerates | Director/Board Member Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director/Board Member | |
Convergent Therapeutics, Inc.
 Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Pharmaceuticals: Major | Chairman | |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| ZOSANO PHARMA CORPORATION | Pharmaceuticals: Major | Director of Finance/CFO |
Statistics
International
| United States | 46 |
| Ireland | 3 |
| Canada | 2 |
Sectoral
| Health Technology | 32 |
| Consumer Services | 9 |
| Finance | 6 |
| Commercial Services | 4 |
| Technology Services | 2 |
Operational
| Director/Board Member | 138 |
| Corporate Officer/Principal | 63 |
| Independent Dir/Board Member | 49 |
| Chief Tech/Sci/R&D Officer | 24 |
| Undergraduate Degree | 23 |
Most connected contacts
| Insiders | |
|---|---|
| Luke Evnin | 42 |
| Alan Colowick | 30 |
| Ron Hunt | 29 |
| Mark Chin | 25 |
| Patrick Baeuerle | 19 |
| Scott Myers | 18 |
| Joanne Viney | 18 |
| Georgia Erbez | 18 |
| Julia Eastland | 16 |
| Lauren Silvernail | 14 |
| Gerald McMahon | 13 |
| Natalie Sacks | 13 |
| Joseph Bailes | 12 |
| Andrew Robbins | 11 |
| Jonathan Drachman | 10 |
- Stock Market
- Insiders
- Rachael Lester
- Company connections
